Patents by Inventor Mary Rea

Mary Rea has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for the treatment of C. difficile
    Patent number: 11896628
    Abstract: Disclosed herein are compositions and methods for preventing, ameliorating, or treating Clostridium difficile infections and/or reducing the severity of one or more risk factors, signs, or symptoms associated with C. difficile infections. In particular, the technology of the present disclosure relates to methods for administering an effective amount of a composition comprising strains of Bacillus amyloliquefaciens bacteria identified as ART24, ART4, and ART 12, to a subject suffering from or at risk for C. difficile infections.
    Type: Grant
    Filed: July 1, 2022
    Date of Patent: February 13, 2024
    Assignee: Artugen Therapeutics Ltd.
    Inventors: Ronald Farquhar, Christopher K. Murphy, Colin Hill, Paul Ross, Mary Rea, Michelle O'Donnell, Brian Healy, Laurent Chesnel
  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF C. DIFFICILE
    Publication number: 20230132133
    Abstract: Disclosed herein are compositions and methods for preventing, ameliorating, or treating Clostridium difficile infections and/or reducing the severity of one or more risk factors, signs, or symptoms associated with C. difficile infections. In particular, the technology of the present disclosure relates to methods for administering an effective amount of a composition comprising strains of Bacillus amyloliquefaciens bacteria identified as ART24, ART4, and ART 12, to a subject suffering from or at risk for C. difficile infections.
    Type: Application
    Filed: July 1, 2022
    Publication date: April 27, 2023
    Applicant: Artugen Therapeutics Ltd.
    Inventors: Ronald Farquhar, Christopher K. Murphy, Colin Hill, Paul Ross, Mary Rea, Michelle O'Donnell, Brian Healy, Laurent Chesnel
  • Methods and compositions for the treatment of C. difficile
    Patent number: 11419900
    Abstract: Disclosed herein are compositions and methods for preventing, ameliorating, or treating Clostridium difficile infections and/or reducing the severity of one or more risk factors, signs, or symptoms associated with C. difficile infections. In particular, the technology of the present disclosure relates to methods for administering an effective amount of a composition comprising strains of Bacillus amyloliquefaciens bacteria identified as ART24, ART4, and ART 12, to a subject suffering from or at risk for C. difficile infections.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: August 23, 2022
    Assignee: Artugen Therapeutics Ltd.
    Inventors: Ronald Farquhar, Christopher K. Murphy, Colin Hill, Paul Ross, Mary Rea, Michelle O'Donnell, Brian Healy, Laurent Chesnel
  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF C. DIFFICILE
    Publication number: 20210220411
    Abstract: Disclosed herein are compositions and methods for preventing, ameliorating, or treating Clostridium difficile infections and/or reducing the severity of one or more risk factors, signs, or symptoms associated with C. difficile infections. In particular, the technology of the present disclosure relates to methods for administering an effective amount of a composition comprising strains of Bacillus amyloliquefaciens bacteria identified as ART24, ART4, and ART 12, to a subject suffering from or at risk for C. difficile infections.
    Type: Application
    Filed: June 6, 2019
    Publication date: July 22, 2021
    Inventors: Ronald Farquhar, Christopher K. Murphy, Colin Hill, Paul Ross, Mary Rea, Michelle O'Donnell, Brian Healy, Laurent Chesnel
  • Thuricin CD, an antimicrobial for specifically targeting
    Patent number: 8852917
    Abstract: The present invention relates to a new bacteriocin, to microbial strains which can produce it and to uses of the bacteriocin and the strains. The bacteriocin is effective against Clostridium difficile and Listeria monocytogenes amongst other organisms.
    Type: Grant
    Filed: November 28, 2008
    Date of Patent: October 7, 2014
    Assignees: University College Cork, TEAGASC, The Agriculture and Food Development Authority
    Inventors: Colin Hill, Mary Rea, Paul Ross
  • THURICIN CD, AN ANTIMICROBIAL FOR SPECIFICALLY TARGETING CLOSTRIDIUM DIFFICILE
    Publication number: 20110059060
    Abstract: The present invention relates to a new bacteriocin, to microbial strains which can produce it and to uses of the bacteriocin and the strains. The bacteriocin is effective against Clostridium difficile and Listeria monocytogenes amongst other organisms.
    Type: Application
    Filed: November 28, 2008
    Publication date: March 10, 2011
    Inventors: Colin Hill, Mary Rea, Paul Ross